Mg Of Estradiol Valerate Research Articles

Ultrasonography and endocrinology of ovarian dysfunctions induced in heifers with estradiol valerate

This study monitored the long-term follicular dynamics and changes in ovarian steroid hormones associated with an experimental model of cystic ovarian degeneration (COD) in the heifer. In the treated group (n = 7), Holstein heifers received a single injection of 500 μg of cloprostenol (prostaglandin F2 a, PG) and 5 mg of estradiol valerate (EV) on either Day 17, 18 or 19 of the estrous cycle. The control group (n = 7) received only PG. Transrectal ultrasound was performed daily, beginning 8 to 10 d before injection and continuing until a return to normal cyclicity (40 to 74 d). Blood samples were taken twice daily over the same period. The EV disrupted the normal follicular development as well as the plasma progesterone and estradiol profiles of 6/7 heifers in the treated group. Two different types of responses were observed. The Type-I response (n = 2) was characterized by a premature ovulation followed by a corpus luteum (CL) which persisted for over 30 d. The Type-II response (n = 4) was characterized by anovulation followed by the emergence of a large ovarian structure which could further be subtyped. In Type- IIA (n = 2), this follicle ovulated at an exaggerated size of 19 or 24 mm (mean diameter of controls: 13.4 ± 2.7 mm). The subsequent cavernous CL was very large at 35 and 37 mm (mean diameter of CL in controls: 23.8 ± 2.0 mm). In Type- IIB (n = 1), the follicle present at the time of injection continued to grow and became a luteinized cyst. In Type-IIC (n = 1), several waves of follicular cysts developed and persisted for 52 d. This study suggests that EV induces a range of ovarian dysfunctions including different forms of COD. The individual differences in the stage of folliculogenesis at the time of injection of EV may be responsible for the different types of responses.

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses

OBJECTIVE: Our purpose was to study the effects of intrauterine release of a daily dose of 20 μg levonorgestrel by an intrauterine device on climacteric symptoma, bleeding pattern, and endometrial histologic features in postmenopausal women receiving transdermal estrogen replacement therapy. STUDY DESIGN: Forty parous postmenopausal women were randomly allocated into two groups for 1 year: 20 women receiving a continuous transdermal daily dose of 50 μg of estradiol had a levonorgestrel-releasing intrauterine contraceptive device inserted, and the control group of 20 women received a continuous oral dose of 2 mg of estradiol valerate and 1 mg of norethisterone acetate daily. The climacteric symptoms, bleeding patterns, endometrial thickness, and endometrial changes in biopsy samples were analyzed. Serum levels of estradiol in both groups and levonorgestrel levels in the intrauterine device group were also determined. RESULTS: Both treatment regimens effectively relieved climacteric symptoms. Spotting was more common in the intrauterine contraceptive device group than in the oral therapy group for the first 3 months. After that, the proportion of women without any bleeding was similar in both groups. Two patients in each group dropped out because of bleeding. CONCLUSION: These preliminary findings suggest that the levonorgestrel-releasing intrauterine contraceptive device is a useful alternative mode of progestin administration for certain selected women receiving estrogen replacement therapy.

Norgestomet implants synchronize estrus and enhance fertility in beef heifers subsequent to a timed artificial insemination

Three trials involving 128 heifers were conducted to determine whether norgestomet implants administered during the mid- and late luteal phases after breeding could be used to synchronize a second estrus in nonpregnant, inseminated heifers without adversely affecting pregnancy in pregnant heifers. All heifers were initially synchronized with Syncro-Mate B and artificially inseminated 47 h after implant removal. On d 9 (Trial 1) or d 12 (Trial 2) after the timed AI, the heifers were randomly assigned to treated or control groups. Treated heifers received two silicone implants containing 10.0 mg of norgestomet each (Trial 1) or one silicone implant containing 3.6 mg of norgestomet (Trial 2). Silicone implants were removed on d 21 after the initial AI. In Trial 1, the calving rate to the initial AI of the control heifers was 35 vs 55% for the norgestomet-implanted heifers (P > .05). In Trial 2 the calving rate to the initial AI of the control heifers was 9 vs 45% in the treated heifers (P < .01). At the return estrus 52% of the control heifers returned to estrus within a 3-d period, whereas 93% of the norgestomet-treated heifers returned to estrus within a 3-d period (P < .01). Norgestomet treatment had no effect on serum progesterone concentrations of the pregnant heifers on d 21 after the initial AI. In Trial 3, both control and treated heifers were administered silicone implants containing 3.6 mg of norgestomet on d 12; additionally, the treated heifers received an injection containing 3.0 mg of norgestomet and 5.0 mg of estradiol valerate. Norgestomet implants were removed on d 21.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of metestrous administration of a norgestomet implant and injection of norgestomet and estradiol valerate on luteinizing hormone release and development and function of corpora lutea in suckled beef cows.

Sixteen suckled beef cows were used to determine effects of Syncro-Mate-B (SMB) on the development and function of corpora lutea (CL) and LH release. Twelve cows were treated 2 d after estrus with the standard SMB treatment regimen, a 6-mg Norgestomet ear implant (in situ 9 d) and a 2-mL i.m. injection of 3 mg of Norgestomet and 5 mg of estradiol valerate at time of implant insertion. Four cows served as untreated controls. In cows treated with SMB with subsequently nonfunctional CL (n = 5), mean concentrations of progesterone (P4) were lower on d 9, 12 (implant removal), and 14 of the treated cycle than in control cows or in those cows treated with SMB that developed functional CL (P < .01). In cows treated with SMB that developed functional CL (n = 7), mean concentrations of P4 were lower only on d 12 of the treated cycle than those in control cows (P < .01). In cows treated with SMB with subsequently nonfunctional CL, CL were smaller from d 9 through 14 of the treated cycle than in control cows or in those cows treated with SMB that developed functional CL (P < .01). In cows treated with SMB that developed functional CL, CL were smaller on d 9 and 11 of the treated cycle than in control cows (P < .01). Regardless of subsequent CL function, mean concentrations of LH and numbers of LH pulses were lower in cows treated with SMB than in control cows on d 3 and 4 of the treated cycle (P < .01).(ABSTRACT TRUNCATED AT 250 WORDS)

Synchronization of estrus in dairy goats given norgestomet and estradiol valerate at various stages of the estrous cycle

Summary Dairy goats were given subcutaneous implants with 3 mg of norgestomet (nor) and im injections of 0.625 mg of estradiol valerate and 0.375 mg of norgestomet on day 0 of the estrous cycle (estrus; nor 0, n = 18), on postestrus day 4 (nor 4, n = 18), or on postestrus day 11 (nor 11, n = 15). Ear implants were removed after 9 days. Mean (± se) hours from removal of ear implants to onset of estrus and proportion of goats responding were 36 ± 3.8 and 83%, 33 ± 4.0 and 61%, and 36 ± 2.7 and 93% for groups nor 0, nor 4, and nor 11, respectively. There were no significant differences between treatment groups in time to onset of estrus. The percentage of goats in group nor 11 that had signs of estrus was significantly greater than the percentage of goats in group nor 4. Of the goats in groups nor 0, nor 4, and nor 11 that had signs of estrus, 53, 55, and 86%, respectively, had onset of behavioral estrus between 24 and 48 hours after implant removal. All goats that had signs of estrus had onset of behavioral estrus between 12 and 72 hours after implant removal. Mean (± se) hours from removal of ear implants to time of peak concentrations of luteinizing hormone (lh) were 49 ± 4.1, 49 ± 3.8, and 49 ± 4.0 for groups nor 0, nor 4, nor 11, respectively (not different). The percentage of goats in group nor 11 that had lh peaks was significantly greater than the percentage of goats in group nor 4. Of the goats that had estrus, there was no difference between groups in the percentage, which also had an lh peak. On the basis of progesterone profiles from does in group nor 0, functional corpora lutea had formed in 3 of 18 does while the ear implants were in place. In group nor 4, concentrations of progesterone were &lt; 1.0 ng/ml in 6 of 18 does at the time of implant placement, suggesting that these does had not formed functional corpora lutea by postestrus day 4. Eight of 18 does in group nor 4 had concentrations of progesterone &gt; 1.0 ng/ml at 48 hours after implant removal, suggesting that the estradiol valerate in the injection had not prevented the formation of functional corpora lutea after the previous estrus in these animals. All does in group nor 11 had concentrations of progesterone &gt; 1 ng/ml on the day of implant placement. Progesterone concentrations had decreased to &lt; 1 ng/ml in all but 1 doe in group nor 11 by the day of implant removal, suggesting that the corpora lutea from the previous estrous cycle had undergone luteolysis prior to the time of implant removal in most of these animals. This method of synchronization of estrus was effective in dairy goats, although goats that were in the early luteal phase at the time of treatment did not respond consistently.

Luteal function and reproductive response in suckled beef cows after metestrus administration of a norgestomet implant and injection of estradiol valerate with various dosages of injectable norgestomet.

In an experiment replicated over 2 yr, 149 suckled beef cows were administered Syncro-Mate-B (SMB), a 6-mg Norgestomet (NOR) ear implant (in situ 9 d) in conjunction with an i.m. injection of 5 mg of estradiol valerate (EV), and either 3.0, 4.5, or 6.0 mg of NOR, 2 d after estrus. All cows were artificially inseminated at 48 h (timed insemination; TI) after implant removal (IR) and cows were reinseminated at any estrus subsequent to 24 h of TI through 30 d. Blood samples collected before treatment, every 3 d through IR, and at TI were assayed for progesterone (P4). At TI, 44, 39, and 12% of cows treated with 3.0, 4.5, or 6.0 mg of NOR, respectively, had serum concentrations of P4 greater than 1 ng/mL (3.0 and 4.5 mg vs 6.0 mg, P less than .01). Fifty-eight, 63, and 84% of cows treated with 3.0, 4.5, or 6.0 mg of NOR, respectively, exhibited a synchronized (within 5 d of IR) estrus (3.0 and 4.5 mg vs 6.0 mg, P less than .05). Pregnancy rates for the 5-d synchronized period were 38, 45, and 66% for cows treated with 3.0, 4.5, or 6.0 mg of NOR, respectively (3.0 and 4.5 mg vs 6.0 mg, P less than .05). First-service pregnancy rates were 66, 71, and 79% for cows treated with 3.0, 4.5, or 6.0 mg of NOR, respectively (P greater than .10).(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of exogenous estradiol-17 beta on luteinizing hormone, progesterone, and estradiol-17 beta concentrations before and after prostaglandin F2 alpha-induced termination of pregnancy and pseudopregnancy in gilts.

This study evaluated the influence of exogenous estradiol-17 beta (E2) administration on LH concentrations and the number of animals returning to estrus after the termination of pregnancy or pseudopregnancy in gilts. Gilts were mated (pregnant; n = 11) on the 1st d of estrus or received 5 mg of estradiol valerate i.m. at d 11 to 15 after the onset of estrus (pseudopregnant; n = 9). Gilts were treated with prostaglandin F2 alpha (PGF2 alpha, 15 and 10 mg) at 12-h intervals on d 44 of pregnancy or pseudopregnancy. The day of abortion or luteolysis (progesterone less than .2 ng/mL) was considered d 0. Six pregnant and four pseudopregnant gilts received s.c. an E2 capsule (24 mg of E2) on d -20 and additional E2 capsules on d -13 and -6. The E2 capsules were removed on the day after PGF2 alpha administration. Blood samples were collected at 12-h intervals from d -21 to -3, at 6-h intervals from d -2 to 21 or the onset of estrus, and at 15-min intervals for 8 h on d -2, 1, 4, 7, 10, 14, and 18. After each 8-h sampling period, gilts were treated i.v. with GnRH at .5 micrograms/kg of BW and blood samples collected at 10-min intervals for 3 h. A greater (P less than .05) proportion of sham-treated gilts than of E2-treated gilts exhibited a preovulatory-like LH surge after abortion/luteolysis. It was evident that E2 supplementation before luteolysis reduced the ability of pregnant and pseudopregnant gilts to return to estrus.

Is 1 mg of estradiol valerate or 0.625 mg of conjugated estrogens sufficient for all women to prevent menopausal bone loss?

Bone mineral content was measured by dual photon absorptiometry in 35 women who needed estrogen replacement therapy but did not want the addition of progestogens because they did not want regular bleeding. A total of 23 women were treated with estradiol valerate 1 mg per day over a mean period of 3.7 years; 12 women received conjugated estrogens 0.625 mg per day over a mean period of 5.3 years. The mean values of bone mineral content in both groups did not change. In the women on estradiol valerate, 61% had a decrease, and in those on conjugated estrogens, 67% had a decrease in bone mineral content. However, the calculated decrease per year was within the limits of the intraindividual reproducibility of the measurements. A difference between two measurements with a decrease of > 1.0 g hydroxyapatite/year over a period of > 3 years is larger than the limits of the intraindividual reproducibility. A decrease in bone mineral content > 1.0 g hydroxyapatite/year over a mean period of 3.98 years, SD 0.35, was observed in six of 23 (26%) of the women on estradiol valerate with a mean decrease of 5.28 g hydroxyapatite, SD 0.97. Only one of 12 (8%) of the women on conjugated estrogens had a decrease of 6.1 g hydroxyapatite over a period of 5.2 years. Periodic measurement of bone mineral is recommended in women on estrogen replacement therapy with estradiol valerate 1 mg per day or conjugated estrogens 0.625 mg per day for prevention of postmenopausal bone loss.

Luteal function, estrous response, and pregnancy rate after treatment with Norgestomet and various dosages of estradiol valerate in suckled cows.

Two experiments were conducted to determine whether dosage of estradiol valerate (EV) or day of estrous cycle when treatment was administered affected response to Syncro-Mate-B (SMB). Suckled beef cows received a 6-mg Norgestomet (NOR) ear implant (in situ 9 d) and a 3-mg NOR i.m. injection. In Exp. 1, 74 cows received NOR treatments concurrently with either 5 or 6 mg of EV administered i.m. on either d 1, 3, or 5 of an estrous cycle (estrus = d 1). In Exp. 2, 169 cows received NOR treatments concurrently with either 5, 7, or 9 mg of EV administered i.m. on either d 3 or 9 of an estrous cycle. In Exp. 1, 67, 50 and 92%, respectively, of cows receiving 5 mg of EV on d 1, 3, or 5 had functional corpora lutea (CL) at implant removal, whereas 42, 75, and 77%, respectively, of cows receiving 6 mg of EV had functional CL at implant removal (dosage P greater than .10; day P less than .05). Synchronized estrous responses were 50, 33, and 23%, respectively, when cows received 5 mg of EV on d 1, 3, or 5, and 67, 33, and 38%, respectively, when cows received 6 mg of EV (dosage P greater than .10; day P less than .05). First-service pregnancy rate was decreased (P less than .05) in cows treated on d 5 (33%) compared with cows treated on d 1 (63%), but dosage of EV had no effect on pregnancy rate.(ABSTRACT TRUNCATED AT 250 WORDS)

African green monkeys have sexually dimorphic and estrogen-sensitive hypothalamic neuronal membranes

Previous studies have shown sex differences in intramembrane particle content in the arcuate neurons of the rat hypothalamus. In this study, freeze-fracture replicas were prepared from the infundibular hypothalamus of adult African green monkeys ( Cercopithecus aethiops) in order to determine whether primates also have sexual dimorphism in neuronal membranes. Intramembrane particles (IMP) were quantitatively assessed in the perikaryal plasma membranes of infundibular neurons. Four groups of monkeys were studied: intact males, intact females, ovariectomized females injected with 20 mg of estradiol valerate over 10 days and ovariectomized females injected with vehicle (castor oil). Membranes from females showed an increased numerical density of IMPs when compared to males. Ovariectomy of females did not affect IMP content, while estrogen administration resulted in a significant decrease in IMP numerical density to reach male values. These findings indicate a sex difference in neuronal membranes in the hypothalamus of monkeys and suggest that as in rodents, neuronal plasma membrane organization in higher primates may be modulated by gonadal steroids.

Syncro-mate B ® induces estrus in ovariectomized cows and heifers

Eleven ovariectomized Hereford × Simmental cows and 10 ovariectomized crossbred heifers (primarily Angus and Hereford) were given the Syncro-Mate B (SMB) estrous synchronization treatment. The SMB treatment consisted of a 2 ml i.m. injection containing 5 mg of estradiol valerate and 3 mg of norgestomet plus a hydron ear implant containing 6 mg of norgestomet. The ear implant was removed 9 d later. Cows and heifers were considered in estrus only if they stood for mounting by a herdmate or a bull. Observations for estrus were made four or six times each day for 3 d after implant removal. The 21 animals were used in eight trials. Each trial involved 9 or 11 cows or 5 or 10 heifers. Four days to three weeks elapsed between implant removal and implant insertion for the next trial. No ovariectomized cow or heifer was observed in estrus for 21 d before treatment with SMB. In the eight trials, 3 of 9, 7 of 9 and 6 of 11 cows exhibited estrus, whereas 5 of 10, 1 of 5, 3 of 5, 3 of 5 and 5 of 5 heifers exhibited estrus after treatment. When data were pooled, 16 of 29 (55.2%) cows and 17 of 30 (56.7%) heifers exhibited estrus after treatment. Our data indicate that the SMB treatment can induce estrus in cows and heifers, independently of the ovaries.

Effect of treatment with estradiol valerate on endocrine changes and ovarian follicle populations in dairy cows

A linear-array ultrasound instrument was used to monitor the dynamics of follicular cyst formation following estradiol valerate (EV) administration in postpartum dairy cattle. Twelve cyclic cows were given two intramuscular (i.m.) injections of prostaglandin and F 2α (PGF 2α) 12 d apart to synchronize estrus. On Day 16 (Day 0 = day of estrus) six cows received 10 mg of EV in 1 ml sesame oil; the remaining six cows were treated with 1 ml sesame oil. The ovaries of all cows were scanned rectally each morning from Day 9 until 14 or 30 d post treatment. Plasma concentrations of luteinizing hormone (LH) and progesterone (P 4) were also determined as objective indices of treatment effects. Day 0 to 16 ultrasound pictures of the ovaries of both control and treated cows were characterized by the presence of a corpus luteum (CL; 19 to 38 mm), several small follicles (<5 mm) and a medium-sized follicle (6 to 28 mm). Following treatment in control cows, the CL regressed gradually, and a preovulatory follicle was identifiable by Day 17 to 18, it increased in size and reached a maximum of 28 to 30 mm by Day 20 after ovulation and was identifiable throughout the rest of the cycle. Administration of 0 mg of EV resulted in a rapid reduction in the size of the CL. Growth of a large follicle was observed in all treated animals around Days 16 to 20, but having reached a maximum diameter of 12 to 24 mm it regressed without resulting in ovulation. Subsequent ultrasound pictures of EV-treated cows were characterized by the absence of a new CL and the presence of medium-sized persistent follicles. Estradiol valerate treatment induced early luteolysis (43 ± 05 h post EV vs 101 ± 22 h) and an LH surge (41 ± 11 h vs 125 ± 17 h).

Glial peroxidase activity in the hypothalamic arcuate nucleus: effects of estradiol valerate-induced persistent estrus

To test the hypothesis that stimulation of glial peroxidase activity by estrogens may play a role in the pathogenesis of the previously reported degenerative changes in the hypothalamic arcuate nucleus that occur in female rats treated with a long-acting estrogen preparation, the cellular localization and number of peroxidase-positive granules in the hypothalamus were determined in adult female rats treated with a single intramuscular injection of 2 mg of estradiol valerate. The persistent estrus state, manifested as persistent vaginal conrnification and polycystic ovaries, was induced in 80% of the animals. In comparison with normally cycling controls, the arcuate nuclei of persistent estrus rats exhibited a 3- and 2.8-fold increase in numbers of diaminobenzidine-positive granules and granule clusters, respectively (P < 0.01 for both comparisons). These peroxidase-positive granules were identified in astrocytes by double-label immunohistochemistry utilizing antiserum to glial fibrillary acidic protein. Diaminobenzidine staining occurred over a pH range of 4–10.5 and was resistant to the catalase inhibitor, aminotriazole, and to tissue pre-heating, indicating that the histochemical reaction was not due to tissue enzyme activity. Rather, these findings indicate that a non-enzymatic, pseudoperoxidation reaction has been induced in these cells by estrogen administration. Possible mediators of this reaction are metallo-porphyrins known to be present in rodent hypothalamus. The mechanisms by which astrocyte peroxidase activity may play a role in estrogen-related neural damage are discussed.

Uterine secretory alterations coincident with embryonic mortality in the gilt after exogenous estrogen administration.

Sixteen crossbred gilts were assigned randomly to receive either an i.m. injection of sesame oil (control) or estrogen (E), 5 mg of estradiol valerate, on d 9 and 10 of pregnancy. Gilts were unilaterally hysterectomized on either d 12 and 14 or 16 and 18. Uterine horns were flushed with 20 ml of .9% sterile NaCl solution to recover conceptus tissue. Conceptuses and endometrial explants were cultured for 24 h with 100 microCi [3H] leucine in 15 ml of minimum essential media. After dialysis, culture media were submitted to 2D-polyacrylamide gel electrophoresis and incorporated proteins were analyzed by fluorography. Normal, intact conceptus tissue was recovered from control gilts. Estrogen-treated gilts flushed on d 12 and 14 contained intact conceptuses; however, uteri from two gilts on d 16 and three on d 18 contained degenerating conceptus tissue. Comparison of endometrial polypeptides synthesized in vitro indicated an alteration in E-treated gilts on d 12 through 18. Although similar polypeptides were present, a band of polypeptides with a Mr of approximately 30,000 and pI from 7.9 to 8.9 and a larger, acidic polypeptide (Mr = 100,000, pI 3.5 to 5.0) were faint or absent in E-treated gilts. Conceptuses elongated normally in the altered uterine environment, but failed to survive past d 14 in E-treated gilts. Although loss of specific polypeptides in E-treated gilts coincides with conceptus death, their function in conceptus development or attachment is unknown.

A comparison of the effects of ethinyl estradiol and estradiol valerate on serum and lipoprotein lipids

Serum lipids and lipoproteins were assessed after treatment with 2 mg of oestradiol valerate (E 2V) and 10 μg of ethinyl oestreadiol (EE) in a group of 24 oophorectomised women in a study with an open cross-over design. E 2V in this oral dose was quite inert in its effect on lipoprotein lipids. Ten micrograms of EE is a dose which in most women is sufficient to alleviate post-menopausal vasomotor symptoms. However, this low dose of EE increased serum triglycerides as a result of increased levels in the ultracentrifugally isolated lipoprotein fractions. Increased levels of serum and lipoprotein triglycerides are considered cardiovascular risk factors in women.

The sequential use of estradiol and prostaglandin E2 topical gels for cervical ripening in high-risk term pregnancies requiring induction of labor

We compared the safety and efficiency of 200 mg of estradiol valerate prepared as a topical cervical gel as a preripening agent when used 6 hours before the application of 2 mg of prostaglandin E2 gel for the purpose of cervical ripening in 40 high-risk obstetric patients before indicated oxytocin induction of labor. When compared with a placebo prostaglandin E2 dosage, the estradiol had no effect on the change of Bishop score, length of labor, amount of oxytocin required, or the cesarean delivery rate. While no uterine contractions were noted after the application of the estradiol, 85% of patients had recordable uterine activity after the application of prostaglandin E2, suggesting that even at the 2 mg dosage this sequential regimen is not appropriate for local cervical ripening.

Induction of ovulatory oestrus in true anoestrous buffaloes during low breeding season

A fertility treatment trial of anoestrous buffaloes was undertaken on a well managed dairy farm in the low breeding season. Forty lactating buffaloes, 12 each from first and second parity and 16 from third or higher parity, not seen in oestrus for at least 3 to 5 months were diagnosed anoestrous by rectal examination. A subcutaneous ear implant containing 3 mg of norgestomet was inserted, accompanied by an intramuscular injection of 3 mg norgestomet and 5 mg of oestradiol valerate (Syncro-mate B, Intervet). After 9 days the implant was removed and 600 IU of PMSG (Intervet) were given intramuscularly. Irrespective of oestrous behaviour, the animals were inseminated with frozen semen at two fixed times: 48 and 72 h after removal of the implant. Thirty animals having calved in the same period as the experimental animals and not seen in oestrus since then served as controls. Milk samples for progesterone analysis were taken on the day of insertion of the implant, the day of removal and on days 10 and 22 after the second A.I. Progesterone determination by means of an enzyme immunoassay (EIA) revealed that 33 buffaloes out of 40 (82.5%) were in true anoestrus. Ovulation occurred in 21 buffaloes out of 30 (70%). Three buffaloes could not be followed up further. The overall conception rate was 53.3%. The parity-wise conception rate was 40%, 44.4% and 72.2% in first, second and third or higher parity, respectively. None of the control animals displayed oestrus during the course of the study.

Effect of feed treatment and exogenous estrogen and progestogen on puberty and lambing rates in ewe lambs.

Four hundred seventy-four ewe lambs (5 to 6 mo of age) were assigned within breed to two postweaning feed treatments; 1 = alfalfa pellets ad libitum and 2 = alfalfa pellets plus 20% barley or wheat ad libitum. Ten days prior to the start of breeding, approximately one-half of the ewe lambs within each feed treatment were treated with a single injection of 2.5 mg of estradiol valerate and 1.5 mg of norgestomet and implanted with 3 mg of norgestomet for 8 d. At the start of breeding, fertile Suffolk rams were fitted with marking harnesses and penned with ewe lambs; evidence of estrus and breeding was determined on a weekly basis by visual examination for breeding marks. In the second year of the study, 7 to 13 d after recording estrous activity, all marked ewe lambs were bled; and blood was assayed for progesterone. In 1983, 60% of the ewe lambs showed estrus and 11% lambed compared with 48% exhibiting estrus and 30% lambing in 1984 (P less than .01). More (P less than .01) ewe lambs on feed treatment 1 displayed estrus, but more (P less than .05) lambed in the feed treatment 2 group. Steroid treatment resulted in more (P less than .01) ewe lambs showing estrus but fewer lambing (P less than .01). Examination of progesterone concentrations for evidence of ovulation and corpus luteum development indicated that treatment with steroids caused a large percentage of ewe lambs to exhibit estrus. However, many of these failed to develop a corpus luteum and become pregnant.(ABSTRACT TRUNCATED AT 250 WORDS)

Phase II randomized clinical trial with norethisterone oenanthate 50 mg alone and in combination with 5 mg or 2.5 mg of either estradiol valerate or cypionate as a monthly injectable contraceptive

A Phase II multicentric study was carried out to compare the different contraceptive treatment schedules of the monthly injectable consisting of norethisterone oenanthate (NET OEN) 50 mg either given alone or in combination with estrogen esters, 2.5 or 5 mg of estradiol valerate (E2 Val.) or estradiol cypionate (E2 Cyp.).A total of 364 women were observed for 1686 months of use. Analysis of the bleeding pattern data indicated that NET OEN 50 mg when given alone gave rise to delayed cycles and/or amenorrhoea. However, the addition of estrogen esters in a dose of either 2.5 or 5 mg provided significantly better bleeding patterns. Of the different treatment schedules investigated, the combination of NET OEN 50 mg with E2 Val. 5 mg provided more consistent and better cycle control. These findings however need further validation on a larger study sample.

Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone

Subfractions of high-density lipoprotein cholesterol and its apolipoproteins were followed up in 58 postmenopausal women during three cycles of unopposed estrogen replacement therapy with 2 mg of estradiol valerate daily. During the last 10 days of the following three cycles the women received sequential addition of either 250 μg of levonorgestrel, 10 mg of medroxyprogesterone acetate, or 200 mg of natural micronized progesterone. Both progestogens significantly decreased total high-density lipoprotein cholesterol as well as subfraction 2 of high-density lipoprotein. Data suggest that doses and relative biologic activity of 19-norsteroids and 17-hydroxyprogesterone derivatives are more important for their metabolic effects than are qualitative differences. Natural progesterone had no apparent influence on high-density lipoprotein cholesterol or its subfractions and may develop into an atractive alternative to synthetic progestogens.